Equity Overview
Price & Market Data
Price: $20.40
Daily Change: +$0.60 / 2.94%
Daily Range: $20.40 - $20.40
Market Cap: $2,825,239,040
Daily Volume: 517
Performance Metrics
1 Week: 3.07%
1 Month: 16.81%
3 Months: 122.2%
6 Months: 155.2%
1 Year: 1,459%
YTD: 123.5%
Company Details
Employees: 137
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.